Manuel Vazquez-Carrera

List of Publications by Year
in descending order

155	8,987	36303 51	46799 89
papers	citations	h-index	g-index

165	165	165	13384
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The PPARÎ±â€“leukotriene B4 pathway to inflammation control. Nature, 1996, 384, 39-43.	27.8	1,329
2	Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends in Endocrinology and Metabolism, 2018, 29, 178-190.	7.1	365
3	Expression of the Peroxisome Proliferator-activated Receptor Î± Gene Is Stimulated by Stress and Follows a Diurnal Rhythm. Journal of Biological Chemistry, 1996, 271, 1764-1769.	3.4	291
4	Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells. Journal of Biological Chemistry, 2008, 283, 11107-11116.	3.4	285
5	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. International Journal of Cardiology, 2013, 168, 3160-3172.	1.7	238
6	Impairment of hepatic Stat-3 activation and reduction of PPARÎ± activity in fructose-fed rats. Hepatology, 2007, 45, 778-788.	7.3	206
7	Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2013, 56, 1372-1382.	6.3	173
8	Targeting endoplasmic reticulum stress in insulin resistance. Trends in Endocrinology and Metabolism, 2015, 26, 438-448.	7.1	172
9	The p65 subunit of NF-ÎºB binds to PGC-1Î±, linking inflammation and metabolic disturbances in cardiac cells. Cardiovascular Research, 2010, 87, 449-458.	3.8	164
10	Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1556-1566.	3.8	161
11	Palmitate Induces Tumor Necrosis Factor-Î± Expression in C2C12 Skeletal Muscle Cells by a Mechanism Involving Protein Kinase C and Nuclear Factor-ÎºB Activation. Endocrinology, 2006, 147, 552-561.	2.8	155
12	Peroxisome proliferator-activated receptor ?/? activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovascular Research, 2005, 65, 832-841.	3.8	154
13	TNF-Î± reduces PGC-1Î± expression through NF-ÎºB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovascular Research, 2009, 81, 703-712.	3.8	147
14	Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E756-E769.	3.5	143
15	The PPARÎ²/Î´ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1Î±-Lipin 1-PPARÎ± Pathway Leading to Increased Fatty Acid Oxidation. Endocrinology, 2011, 152, 1848-1859.	2.8	136
16	Palmitate-Mediated Downregulation of Peroxisome Proliferatorâ€“Activated Receptor-Î³ Coactivator 1Î± in Skeletal Muscle Cells Involves MEK1/2 and Nuclear Factor-ÎºB Activation. Diabetes, 2006, 55, 2779-2787.	0.6	134
17	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1687-1699.	3.8	134
18	Palmitate-Induced Interleukin 6 Production Is Mediated by Protein Kinase C and Nuclear-Factor ÎºB Activation and Leads to Glucose Transporter 4 Down-Regulation in Skeletal Muscle Cells. Endocrinology, 2005, 146, 3087-3095.	2.8	126

#	Article	IF	Citations
19	Atorvastatin Treatment Induced Peroxisome Proliferator-Activated Receptor Î± Expression and Decreased Plasma Nonesterified Fatty Acids and Liver Triglyceride in Fructose-Fed Rats. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 232-239.	2.5	119
20	Nuclear Factor-ÎºB Activation Leads to Down-regulation of Fatty Acid Oxidation during Cardiac Hypertrophy. Journal of Biological Chemistry, 2005, 280, 17464-17471.	3.4	117
21	Bezafibrate Reduces mRNA Levels of Adipocyte Markers and Increases Fatty Acid Oxidation in Primary Culture of Adipocytes. Diabetes, 2001, 50, 1883-1890.	0.6	116
22	Activation of Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-ÎºB Activity via Extracellular Signalâ€“Related Kinase 1/2. Diabetes, 2008, 57, 2149-2157.	0.6	108
23	The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases. Expert Opinion on Therapeutic Targets, 2017, 21, 291-304.	3.4	96
24	SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. Signal Transduction and Targeted Therapy, 2020, 5, 14.	17.1	87
25	Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. Journal of Nutritional Biochemistry, 2011, 22, 741-751.	4.2	86
26	PPARÎ²/Î´ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2014, 57, 2126-2135.	6.3	83
27	Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-ÎºB activation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1687, 76-83.	2.4	81
28	Activation of Peroxisome Proliferator-Activated Receptor-Î´ by GW501516 Prevents Fatty Acid-Induced Nuclear Factor-ÎºB Activation and Insulin Resistance in Skeletal Muscle Cells. Endocrinology, 2010, 151, 1560-1569.	2.8	80
29	Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochemical and Biophysical Research Communications, 2004, 318, 265-274.	2.1	79
30	Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology, 2008, 48, 1506-1516.	7.3	79
31	Hepatic regulation of VLDL receptor by PPARÎ²/Î´ and FGF21 modulates non-alcoholic fatty liver disease. Molecular Metabolism, 2018, 8, 117-131.	6.5	77
32	Alliin, a Garlic (Allium sativum) Compound, Prevents LPS-Induced Inflammation in 3T3-L1 Adipocytes. Mediators of Inflammation, 2013, 2013, 1-11.	3.0	72
33	Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends in Pharmacological Sciences, 2020, 41, 199-208.	8.7	68
34	PPARÎ²/Î´ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 59-67.	2.4	66
35	PPARÎ²/Î´: A Key Therapeutic Target in Metabolic Disorders. International Journal of Molecular Sciences, 2018, 19, 913.	4.1	66
36	Activation of Peroxisome Proliferatorâ€“Activated Receptor-Î²/-Î´ (PPAR-Î²/-Î´) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6â€“Stimulated Adipocytes. Diabetes, 2011, 60, 1990-1999.	0.6	64

#	Article	IF	Citations
37	Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?. Trends in Pharmacological Sciences, 2018, 39, 452-467.	8.7	62
38	Atorvastatin reverses age-related reduction in rat hepatic PPARÎ± and HNF-4. British Journal of Pharmacology, 2005, 145, 853-861.	5.4	61
39	The peroxisome proliferator-activated receptor Î²/Î´ (PPARÎ²/Î´) agonist GW501516 prevents TNF-Î±-induced NF-ÎºB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochemical Pharmacology, 2011, 81, 534-543.	4.4	61
40	Peroxisome Proliferator-Activated Receptor (PPAR)Î² /Î´: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome. Current Molecular Pharmacology, 2009, 2, 46-55.	1.5	60
41	Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. European Journal of Clinical Pharmacology, 2004, 59, 855-861.	1.9	59
42	The peroxisome proliferator-activated receptor (PPAR) Î²/Î´ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia, 2012, 55, 743-751.	6.3	59
43	Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. Journal of Lipid Research, 2004, 45, 2015-2024.	4.2	58
44	Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology, 2009, 49, 106-115.	7.3	58
45	PPARÎ²/Î´ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. International Journal of Cardiology, 2014, 174, 110-118.	1.7	58
46	Transcriptional control of physiological and pathological processes by the nuclear receptor PPARÎ²/Î´. Progress in Lipid Research, 2016, 64, 98-122.	11.6	58
47	Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. British Journal of Pharmacology, 1999, 127, 1479-1485.	5.4	57
48	Increased Reactive Oxygen Species Production Down-regulates Peroxisome Proliferator-activated Î± Pathway in C2C12 Skeletal Muscle Cells. Journal of Biological Chemistry, 2002, 277, 10100-10107.	3.4	55
49	Impaired expression of NADH dehydrogenase subunit 1 and PPARÎ³ coactivator-1 in skeletal muscle of ZDF rats. Journal of Lipid Research, 2004, 45, 113-123.	4.2	55
50	Unraveling the Effects of PPARÎ²/Î´ on Insulin Resistance and Cardiovascular Disease. Trends in Endocrinology and Metabolism, 2016, 27, 319-334.	7.1	55
51	High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids, 2002, 37, 445-454.	1.7	52
52	Cyclooxygenase 2 Inhibition Exacerbates Palmitate-Induced Inflammation and Insulin Resistance in Skeletal Muscle Cells. Endocrinology, 2010, 151, 537-548.	2.8	52
53	Uncoupling Protein-3 mRNA Levels Are Increased in White Adipose Tissue and Skeletal Muscle of Bezafibrate-Treated Rats. Biochemical and Biophysical Research Communications, 1999, 260, 547-556.	2.1	45
54	TNF-Î± inhibits PPARÎ²/Î´ activity and SIRT1 expression through NF-ÎºB in human adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 1177-1185.	2.4	45

#	Article	IF	Citations
55	Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene.. Diabetes, 2000, 49, 1224-1230.	0.6	43
56	Leptin down-regulates peroxisome proliferator-activated receptor Î³ (PPARÎ³) mRNA levels in primary human monocyte-derived macrophages. Molecular and Cellular Biochemistry, 2005, 275, 173-179.	3.1	43
57	PGC-1Î± Induces Mitochondrial and Myokine Transcriptional Programs and Lipid Droplet and Glycogen Accumulation in Cultured Human Skeletal Muscle Cells. PLoS ONE, 2012, 7, e29985.	2.5	43
58	Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovascular Research, 2005, 66, 141-149.	3.8	42
59	Carnitine palmitoyltransferase-1 up-regulation by PPAR-Î²/Î´ prevents lipid-induced endothelial dysfunction. Clinical Science, 2015, 129, 823-837.	4.3	42
60	GDF15 mediates the metabolic effects of PPARÎ²/Î´ by activating AMPK. Cell Reports, 2021, 36, 109501.	6.4	41
61	Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARÎ±. Biochemical Pharmacology, 2004, 67, 157-166.	4.4	40
62	Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism: Clinical and Experimental, 2003, 52, 652-657.	3.4	39
63	Down-regulation of acyl-CoA oxidase gene expression and increased NF-ÎºB activity in etomoxir-induced cardiac hypertrophy. Journal of Lipid Research, 2003, 44, 388-398.	4.2	39
64	PPARÎ²/Î´ and lipid metabolism in the heart. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1569-1578.	2.4	39
65	Relationship between plasma lipids and palmitoylâ€CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. British Journal of Pharmacology, 1994, 112, 551-556.	5.4	38
66	Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARÎ²/Î´-null mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1241-1248.	3.8	37
67	Targeting PPARÎ²/Î´ for the treatment of type 2 diabetes mellitus. Expert Opinion on Therapeutic Targets, 2012, 16, 209-223.	3.4	36
68	miR-146a targets c-Fos expression in human cardiac cells. DMM Disease Models and Mechanisms, 2015, 8, 1081-91.	2.4	35
69	Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. Metabolism: Clinical and Experimental, 2019, 96, 12-21.	3.4	35
70	Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochemical Pharmacology, 2006, 71, 605-614.	4.4	33
71	Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochemical Pharmacology, 2004, 68, 155-163.	4.4	32
72	Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice. Biochemical Pharmacology, 2005, 69, 1195-1204.	4.4	32

#	Article	IF	Citations
73	PGC-1ss Down-Regulation Is Associated With Reduced ERRÂ Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 773-780.	3.6	32
74	Heme-Regulated eIF2Î± Kinase Modulates Hepatic FGF21 and Is Activated by PPARÎ²/Î´ Deficiency. Diabetes, 2016, 65, 3185-3199.	0.6	31
75	Preclinical coronary atherosclerosis in a population with low incidence of myocardial infarction: cross sectional autopsy study. BMJ: British Medical Journal, 2003, 327, 591-592.	2.3	29
76	Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system. Endocrine, 2015, 50, 355-367.	2.3	29
77	VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. Diabetologia, 2017, 60, 2262-2273.	6.3	29
78	The Interplay between NF-kappaB and E2F1 Coordinately Regulates Inflammation and Metabolism in Human Cardiac Cells. PLoS ONE, 2011, 6, e19724.	2.5	28
79	Resveratrol induces nuclear factor-ÎºB activity in human cardiac cells. International Journal of Cardiology, 2013, 167, 2507-2516.	1.7	28
80	Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-ÎºB activity. Acta Diabetologica, 2016, 53, 109-118.	2.5	28
81	Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. British Journal of Pharmacology, 1995, 114, 1351-1358.	5.4	27
82	Peroxisome Proliferator-Activated Receptor Â Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1326-1336.	3.6	26
83	The BACE1 product sAPPÎ² induces ER stress and inflammation and impairs insulin signaling. Metabolism: Clinical and Experimental, 2018, 85, 59-75.	3.4	26
84	Revealing the role of peroxisome proliferator-activated receptor Î²/Î´ in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2021, 114, 154342.	3.4	26
85	SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1Î±-LIPIN 1 pathway and increasing CD36 through Nrf2. Cell Communication and Signaling, 2020, 18, 147.	6.5	25
86	Agonist-induced activation releases peroxisome proliferator-activated receptor Î²/Î´ from its inhibition by palmitate-induced nuclear factor-ÎºB in skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1734, 52-61.	2.4	24
87	GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle. Metabolism: Clinical and Experimental, 2018, 83, 177-187.	3.4	24
88	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	4.0	24
89	Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages. European Journal of Pharmacology, 2002, 451, 11-17.	3.5	23
90	Atorvastatin prevents peroxisome proliferator-activated receptor Î³ coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1736, 120-127.	2.4	23

#	Article	IF	Citations
91	PPAR-Î²/Î´ activation promotes phospholipid transfer protein expression. Biochemical Pharmacology, 2015, 94, 101-108.	4.4	23
92	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, 238, 213-219.	0.8	23
93	Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy. Mini-Reviews in Medicinal Chemistry, 2006, 6, 357-363.	2.4	22
94	The Role of Peroxisome Proliferator-Activated Receptor Î²/Î´ on the Inflammatory Basis of Metabolic Disease. PPAR Research, 2010, 2010, 1-11.	2.4	22
95	Sirtuins: To Be or Not To Be in Diabetic Cardiomyopathy. Trends in Molecular Medicine, 2021, 27, 554-571.	6.7	22
96	Down-Regulation of Acyl-CoA Oxidase Gene Expression in Heart of Troglitazone-Treated Mice through a Mechanism Involving Chicken Ovalbumin Upstream Promoter Transcription Factor II. Molecular Pharmacology, 2003, 64, 764-772.	2.3	21
97	PPARÎ²/Î´ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1049-1058.	3.8	21
98	Effect of ovariectomy on inflammation induced by intermittent hypoxia in a mouse model of sleep apnea. Respiratory Physiology and Neurobiology, 2014, 202, 71-74.	1.6	20
99	Crosstalk between the renin-angiotensin system and the endoplasmic reticulum stress in the cardiovascular system: Lessons learned so far. Life Sciences, 2021, 284, 119919.	4.3	20
100	Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue. Metabolism: Clinical and Experimental, 2003, 52, 351-355.	3.4	19
101	Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague–Dawley rats. Experimental Gerontology, 2004, 39, 1295-1306.	2.8	19
102	Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes. FEBS Letters, 2000, 484, 37-42.	2.8	17
103	Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats 1 1Abbreviations: ACO, acyl-CoA oxidase; Apo, apolipoprotein; APRT, adenosyl phosphoribosyl transferase; CT, CTP:phosphocholine cytidylyl transferase; HDL, high-density lipoprotein; HMG-CoA Rd, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase; LDL, low-density lipoprotein; PAP, phosphatidate phosphohydrolase; PPARÎ±, peroxisome proliferator-activated receptor; SREBP, sterol regulatory element binding protein; and VLDL, very-low-d. Biochemical Pharmacology, 2001, 62, 803-809.	4.4	17
104	Prevention of age-related changes in rat cortex transcription factor activator protein-1 by hypolipidemic drugs. Biochemical Pharmacology, 2004, 68, 1411-1421.	4.4	17
105	Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. Pharmacogenomics, 2008, 9, 1035-1054.	1.3	17
106	Atorvastatin inhibits GSK-3Î² phosphorylation by cardiac hypertrophic stimuli. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 26-35.	2.4	17
107	The PPARÎ²/Î´-AMPK Connection in the Treatment of Insulin Resistance. International Journal of Molecular Sciences, 2021, 22, 8555.	4.1	17
108	Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1â€“7) action on these pathways in cultured human myotubes. Cellular Signalling, 2013, 25, 1318-1327.	3.6	16

#	Article	IF	Citations
109	Transcriptional Regulation by Triiodothyronine of the UDP-glucuronosyltransferase Family 1 Gene Complex in Rat Liver. Journal of Biological Chemistry, 1997, 272, 17171-17175.	3.4	15
110	Cholesterol regulation of genes involved in sterol trafficking in human THP-1 macrophages. Molecular and Cellular Biochemistry, 2005, 273, 185-191.	3.1	15
111	Disodium ascorbyl phytostanol phosphate (FM-VP4), a modified phytostanol, is a highly active hypocholesterolaemic agent that affects the enterohepatic circulation of both cholesterol and bile acids in mice. British Journal of Nutrition, 2010, 103, 153-160.	2.3	15
112	Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients. Biosensors and Bioelectronics, 2019, 136, 38-46.	10.1	15
113	Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. British Journal of Pharmacology, 1995, 116, 2067-2075.	5.4	14
114	Oral administration of a new HRI activator as a new strategy to improve highâ€fatâ€dietâ€induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. British Journal of Pharmacology, 2019, 176, 2292-2305.	5.4	14
115	2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis. Journal of Medicinal Chemistry, 2020, 63, 9237-9257.	6.4	14
116	Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro. Biochemical Pharmacology, 1993, 46, 1791-1796.	4.4	13
117	Inhibition of rat liver microsomal fatty acid chain elongation by gemfibrozil in vitro. FEBS Letters, 1992, 300, 89-92.	2.8	12
118	Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guineaâ€pigs. British Journal of Pharmacology, 1995, 116, 3337-3343.	5.4	12
119	Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. British Journal of Clinical Pharmacology, 1998, 45, 265-269.	2.4	12
120	Etomoxir, Sodium 2-[6-(4-Chlorophenoxy)hexyl]oxirane-2-carboxylate, Up-Regulates Uncoupling Protein-3 mRNA Levels in Primary Culture of Rat Preadipocytes. Biochemical and Biophysical Research Communications, 1999, 263, 87-93.	2.1	12
121	Peroxisome Proliferator-Activated Receptor Î± (PPARÎ±) Activators, Bezafibrate and Wy-14,643, Increase Uncoupling Protein-3 mRNA Levels without Modifying the Mitochondrial Membrane Potential in Primary Culture of Rat Preadipocytes. Archives of Biochemistry and Biophysics, 2000, 380, 353-359.	3.0	12
122	Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. Biochemical Pharmacology, 2001, 61, 357-364.	4.4	12
123	AICAR Protects against High Palmitate/High Insulin-Induced Intramyocellular Lipid Accumulation and Insulin Resistance in HL-1 Cardiac Cells by Inducing PPAR-Target Gene Expression. PPAR Research, 2015, 2015, 1-12.	2.4	12
124	11Î²-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress. Molecular Neurobiology, 2020, 57, 551-565.	4.0	12
125	From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. Journal of Medicinal Chemistry, 2021, 64, 5429-5446.	6.4	12
126	Hypertriglyceridemia and Hepatic Steatosis in Senescence-Accelerated Mouse Associate to Changes in Lipid-Related Gene Expression. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1219-1227.	3.6	11

#	Article	IF	Citations
127	Ritonavir Increases CD36, ABCA1 and CYP27 Expression in THP-1 Macrophages. Experimental Biology and Medicine, 2008, 233, 1572-1582.	2.4	11
128	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. Toxics, 2021, 9, 195.	3.7	11
129	Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 541-551.	2.4	10
130	Endoplasmic reticulum stress downregulates PGC-1Î± in skeletal muscle through ATF4 and an mTOR-mediated reduction of CRTC2. Cell Communication and Signaling, 2022, 20, 53.	6.5	10
131	Cytosolic lipogenic enzymes: Effect of fibric acid derivatives in vitro. Life Sciences, 1993, 52, 213-222.	4.3	9
132	Influence of Lipid Profile and Fatty Acid Composition on the Oxidation Behavior of Rat and Guinea Pig Low Density Lipoprotein. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 119, 311-316.	1.6	9
133	Uncoupling protein-3 mRNA up-regulation in C2C12 myotubes after etomoxir treatment. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1532, 195-202.	2.4	9
134	Gemfibrozil increases the specific binding of rat-cortex nuclear extracts to a PPRE probe. Life Sciences, 2003, 73, 2927-2937.	4.3	9
135	Ageing introduces a complex pattern of changes in several rat brain transcription factors depending on gender and anatomical localization. Experimental Gerontology, 2006, 41, 372-379.	2.8	9
136	Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation. Biochemical Pharmacology, 1993, 46, 1515-1518.	4.4	8
137	PPARs as Key Mediators in the Regulation of Metabolism and Inflammation. International Journal of Molecular Sciences, 2022, 23, 5025.	4.1	7
138	Different response of senescent female Sprague€“Dawley rats to gemfibrozil and rosiglitazone administration. Experimental Gerontology, 2005, 40, 588-598.	2.8	6
139	Inhibition of Cardiac Hypertrophy by Triflusal (4-Trifluoromethyl Derivative of Salicylate) and Its Active Metabolite. Molecular Pharmacology, 2006, 69, 1174-1181.	2.3	6
140	Role of brain c€Jun N€terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high€fat diet pre€clinical model. Journal of Neurochemistry, 2019, 149, 255-268.	3.9	6
141	Pharmacological PPARÎ²/Î´ activation upregulates VLDLR in hepatocytes. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 111-118.	0.8	6
142	Tissue Compatibility of SN€38€Loaded Anticancer Nanofiber Matrices. Advanced Healthcare Materials, 2018, 7, e1800255.	7.6	5
143	Hepatic Gene Expression Changes in an Experimental Model of Accelerated Senescence: The SAM-P8 Mouse. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 1043-1052.	3.6	3
144	Uncovering the role of apolipoprotein C-III in insulin resistance. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 108-115.	0.8	3

#	Article	IF	Citations
145	Inhibidores de HSP90 como futura estrategia terapÃ©utica en la aterosclerosis asociada a diabetes. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2017, 29, 67-68.	0.8	2
146	Pharmacological PPARÎ²/Î´ activation upregulates VLDLR in hepatocytes. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 111-118.	0.2	2
147	CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model. Frontiers in Immunology, 2021, 12, 634797.	4.8	2
148	Peroxisomal Proliferator-Activated Receptor Î²/Î´ Deficiency Induces Cognitive Alterations. Frontiers in Pharmacology, 0, 13, .	3.5	2
149	Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochemical Pharmacology, 2004, 68, 155-155.	4.4	1
150	El Ã¡cido palmÃ¡tico estimula la producciÃ³n de interleucina 6 en cÃ©lulas musculares esquelÃ©ticas por activaciÃ³n de la proteincinasa C y el factor nuclear Î¤B. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2005, 17, 259-269.	0.8	0
151	La activaciÃ³n de receptor activado por proliferadores peroxisÃ³micos Î²/Î´ mejora la resistencia a insulina inducida por IL-6 en cÃ©lulas hepÃ¡ticas. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2012, 24, 275-283.	0.8	0
152	A la bÃºsqueda de la Â«huella metabÃ³licaÂ» en la enfermedad cardiovascular. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 28-29.	0.8	0
153	New Diarylureas as Activators of the Heme-Regulated EIF2Î± Kinase for the Treatment of Type 2 Diabetes Mellitus. Proceedings (mdpi), 2019, 22, .	0.2	0
154	Uncovering the role of apolipoprotein C-III in insulin resistance. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 108-115.	0.2	0
155	Synthesis of a New Family of Soluble Epoxide Hydrolase Inhibitors, in vitro Profiling and in vivo Evaluation in a Murine Model of Acute Pancreatitis. FASEB Journal, 2019, 33, 508.13.	0.5	0